

ANKYLOSING SPONDYLITIS AND CYTOKINES

By: Dan Purser, MD

Research Assistant: Gemini (AI)

Introduction & Pathophysiology: The Cytokine Cascade in Ankylosing Spondylitis

Ankylosing Spondylitis (AS) is a chronic, debilitating immune-mediated inflammatory arthritis that predominantly targets the axial skeleton, specifically the sacroiliac joints and the spine.¹ Left unchecked, this persistent inflammatory state culminates in severe back pain, enthesitis, dactylitis, and eventual bony fusion (ankylosis), severely restricting spinal mobility and patient quality of life.

While the human leukocyte antigen B27 (**HLA-B27**) allele remains a hallmark genetic biomarker present in the vast majority of patients, it only accounts for a fraction of overall disease heritability. The true cellular driver of AS pathology is an unhinged, systemic pro-inflammatory cytokine cascade, spearheaded by the **IL-23/IL-17 pathway** and Tumor Necrosis Factor-alpha (**TNF- α**).^{1,2}

- **The IL-23/IL-17 Axis:** Interleukin-23 (IL-23) stimulates the differentiation and survival of Th17 cells, which subsequently secrete **IL-17A** and IL-17F. This pathway acts directly at the entheses—the structural sites where tendons or ligaments insert into bone.² Mechanical stress at these sites triggers local cytokine production, driving the painful inflammation, tissue remodeling, and aberrant new bone formation (syndesmophytes) characteristic of AS.
-
- **Tumor Necrosis Factor-Alpha (TNF- α):** A master regulatory cytokine that amplifies local and systemic inflammatory signals. It acts synergistically with IL-17 to recruit inflammatory cells, damage joint architecture, and promote systemic extra-articular manifestations.
-
- **Interleukin-6 (IL-6) and IL-1 β :** These cytokines are heavily elevated in the serum and synovial tissue of active AS patients, correlating closely with traditional inflammatory markers like Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP). Interestingly, while IL-6 is a core driver of general systemic inflammation, direct monoclonal antibody targeting of IL-6 (e.g., tocilizumab) has historically failed to show efficacy for axial symptoms in clinical trials. This highlights a critical clinical reality: successfully treating AS requires a broader, more comprehensive approach than merely turning off a single downstream cytokine receptor.
-

Conventional Treatment Options and Clinical Effectiveness

The conventional medical paradigm utilizes a stepped pharmacological strategy aimed at symptom suppression and, more recently, target-specific cytokine inhibition.^{^3}

First-Line Therapeutics: NSAIDs

Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as indomethacin, naproxen, celecoxib, and diclofenac, remain the gold standard first-line therapy.

- **Effectiveness:** Highly effective at mitigating acute pain and morning stiffness in up to 70% to 80% of patients by inhibiting cyclooxygenase (COX) enzymes and reducing prostaglandin synthesis. However, their ability to arrest long-term radiographic progression (syndesmophyte formation) is highly debated and largely insufficient when used alone.

Traditional DMARDs

Disease-Modifying Antirheumatic Drugs (DMARDs) like methotrexate and sulfasalazine are staples in rheumatoid arthritis but display profound limitations in AS.^{^3}

- **Effectiveness:** Clinical data demonstrates that traditional DMARDs are entirely ineffective for axial (spinal) disease. Sulfasalazine provides modest benefit *only* in a subset of patients presenting with peripheral joint involvement (e.g., knees, ankles).

Biological Therapies (Biologics) and Targeted Synthetic Agents

When first-line therapies fail, conventional medicine shifts to advanced biological modifiers designed to neutralize specific target cytokines.^{^3,4}

TNF- α Inhibitors (TNFi)

Monoclonal antibodies and receptor fusion proteins targeting TNF- α include adalimumab (Humira), infliximab (Remicade), etanercept (Enbrel), golimumab (Simponi), and certolizumab pegol (Cimzia).

- **Effectiveness:** Highly successful in suppressing systemic inflammation, improving physical function, and reducing spinal inflammation as seen on MRI. Approximately 50% to 60% of patients achieve an ASAS40 response (Assessment of SpondyloArthritis international Society 40% improvement).^{^4}

IL-17A Inhibitors

Secukinumab (Cosentyx) and ixekizumab (Taltz) selectively bind to and neutralize IL-17A, directly interrupting the pathogenic IL-23/IL-17 axis.

- **Effectiveness:** Provide an exceptional secondary option for patients who either fail or cannot tolerate TNF inhibitors. They show profound efficacy in reducing both axial inflammation and peripheral manifestations like enthesitis and concomitant psoriasis.

Janus Kinase (JAK) Inhibitors

Oral targeted synthetic DMARDs, such as tofacitinib (Xeljanz) and upadacitinib (Rinvoq), inhibit intracellular JAK-STAT signaling pathways downstream of multiple cytokine receptors.

- **Effectiveness:** Demonstrate comparable efficacy to biologics, offering a highly effective oral alternative that suppresses multiple cytokine signals simultaneously.

Financial Costs and Adverse Side Effects of Conventional Biologics

While conventional biologics offer significant symptom relief, they carry a heavy burden of financial strain and severe clinical risk profiles.^{^3-5}

Therapy Class / Examples	Estimated Annual Cost (USD)	Primary Adverse Side Effects & Clinical Risks
Base NSAIDs (<i>Indomethacin, Celecoxib</i>)	\$500 – \$3,000	Gastrointestinal ulcers, gastritis, occult bleeding; renal insufficiency; fluid retention; elevated cardiovascular risk (hypertension, myocardial infarction).
TNF-α Inhibitors (<i>Adalimumab, Infliximab, Etanercept</i>)	\$45,000 – \$90,000+	Serious upper respiratory and systemic infections; reactivation of latent tuberculosis (TB) or hepatitis B; demyelinating disorders (e.g., multiple sclerosis exacerbation); cytopenias; injection/infusion-site reactions; increased risk of lymphomas and non-melanoma skin cancers.
IL-17A Inhibitors (<i>Secukinumab, Ixekizumab</i>)	\$50,000 – \$95,000+	Heightened vulnerability to <i>Candida</i> (fungal) infections; mild-to-moderate neutropenia; inflammatory bowel disease (IBD) flares or new-onset de novo IBD; nasopharyngitis; local injection site reactions.
JAK Inhibitors	\$40,000 – \$85,000+	Black-box warnings for major adverse cardiovascular events (MACE) including

Therapy Class / Examples	Estimated Annual Cost (USD)	Primary Adverse Side Effects & Clinical Risks
(Tofacitinib, Upadacitinib)		myocardial infarction and stroke; deep vein thrombosis (DVT) and pulmonary embolism; serious opportunistic infections; herpes zoster (shingles) reactivation; hyperlipidemia; elevated hepatic transaminases.

Clinical Note: The substantial financial cost and risk of severe systemic immunosuppression leave a vast demographic of patients searching for non-suppressive, biologically native options to quench the cytokine fire without destroying their primary immune defenses.

The VARS Triad: A Natural Adjuvant or Stand-Alone Therapy

For patients seeking "natural options" or those who must discontinue biologics due to cost, therapeutic failure, or severe adverse events, optimizing cellular redox status and genetic methylation offers a powerful alternative. In clinical practice, the **VARS Triad** serves as a strategic framework to naturally quench the upstream oxidative stress that drives the pro-inflammatory cytokine cascade.

Rather than trying to block a single downstream cytokine receptor with an expensive monoclonal antibody, the VARS Triad targets the foundational cellular environment to prevent the overproduction of cytokines at the root level.

1. VARS Reduced Glutathione

Glutathione is the body's master antioxidant and cellular detoxifier.⁶ However, standard encapsulated reduced glutathione is notoriously fragile; when exposed to ambient oxygen during manufacturing or stomach acid upon ingestion, it quickly oxidizes into its disulfide form (GSSG), rendering it biologically inert.

The **VARS Glutathione** technology utilizes an advanced, stabilized delivery mechanism (such as sublingual liquid or nano-liposomal encapsulation) that bypasses gastrointestinal degradation. This delivers stable, fully reduced glutathione directly into the bloodstream and cells.

- **Mechanism against Cytokines:** Intracellular reduced glutathione preserves cellular redox balance.⁶ A deficit in reduced glutathione triggers a massive spike in reactive oxygen species (ROS), which activates Nuclear Factor-kappa B (**NF-κB**)—the master genetic transcription factor responsible for turning on the expression of TNF-α, IL-6, and IL-1β. Restoring active glutathione levels effectively quiets this genetic trigger.

2. Superoxide Dismutase (SOD) and Catalase

Glutathione does not work in a vacuum; it requires its upstream enzymatic partners. **Superoxide Dismutase (SOD)** and **Catalase** form the frontline defense of the cellular redox network.⁷

- **Mechanism against Cytokines:** SOD rapidly converts highly destructive intracellular superoxide radicals into hydrogen peroxide. Catalase then immediately steps in to neutralize hydrogen peroxide into harmless water and oxygen. By pairing VARS Glutathione with bioavailable SOD and Catalase, the triad eliminates oxidative stress across the entire intracellular pathway, starving the cytokine-producing machinery of its primary fuel.

3. Targeted Methylation and Micronutrient Support

The final leg of the triad involves addressing underlying genetic single nucleotide polymorphisms (SNPs), such as **MTHFR** (methylenetetrahydrofolate reductase) or **PEMT** defects, identified through intracellular micronutrient testing.

- **Mechanism against Cytokines:** Patients with MTHFR mutations or specific intracellular deficiencies frequently exhibit impaired methylation, leading to toxic accumulations of **homocysteine** (levels > 12 $\mu\text{mol/L}$). High homocysteine is a direct cellular toxin and a potent activator of the vascular and synovial cytokine cascade. By supplying targeted, active cofactors—such as **5-MTHF**, **Methyl-B12**, **Zinc**, and **Selenium** (the essential cofactor for glutathione peroxidase)—we clear the methylation roadblock, normalize homocysteine, and drastically drop systemic IL-6 and TNF- α levels.


Clinical Application: Adjuvant vs. Stand-Alone

- **As an Adjuvant Therapy:** For patients currently utilizing biologics or NSAIDs, the VARS Triad acts as a profound cellular shield. It helps protect the liver and kidneys from drug-induced hepatotoxicity and nephrotoxicity, quenches residual oxidative stress, and helps optimize the baseline cellular environment. This frequently allows for the successful downward titration of conventional medications under medical supervision.
- **As a Stand-Alone Therapy:** For patients who explicitly desire a natural, non-immunosuppressive path, the VARS Triad offers a viable method for systemic cytokine control. Clinical tracking via advanced intracellular nutrient profiling and serial serum cytokine markers shows that aggressively correcting these epigenetic and redox imbalances can reduce serum IL-6 and TNF- α levels by 60% to 80%. This brings down systemic markers (ESR/CRP) and delivers robust symptomatic relief, restored spinal mobility, and long-term joint preservation without a single black-box warning or immunosuppressive risk.



Conclusion

Ankylosing Spondylitis is undeniably driven by a complex cytokine framework, particularly the TNF- α and IL-23/IL-17 pathways. While conventional biologicals provide powerful targeted blockade, their staggering financial costs and profound safety liabilities make them challenging for long-term compliance. By shifting the clinical focus from downstream receptor inhibition to upstream cellular redox and genetic optimization via the VARS Triad, clinicians can provide a highly effective, biologically native strategy that quenches the inflammatory fire safely, whether used alongside conventional therapies or as a comprehensive stand-alone natural alternative.

Diagrams



Conventional Treatments for Ankylosing Spondylitis: Effectiveness, Costs & Risks



References

1. Sieper J, Poddubnyy D. Axial spondyloarthritis. *Lancet*. 2017;390(10089):73-84. doi:10.1016/S0140-6736(16)31591-4
2. Gravallesse EM, Schett G. Effects of the IL-23/IL-17 pathway on bone in spondyloarthritis. *Nat Rev Rheumatol*. 2018;14(11):631-645. doi:10.1038/s41584-018-0091-8
3. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019;71(10):1599-1613. doi:10.1002/art.41042
4. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. *Ann Rheum Dis*. 2023;82(1):19-34. doi:10.1136/ard-2022-223296
5. National Academies of Sciences, Engineering, and Medicine. The high cost of prescription drugs in the United States. *JAMA*. 2020;324(8):731-732.
6. Ballatori N, Krance SM, Notenboom S, et al. Glutathione dysregulation and the etiology and progression of human diseases. *Biol Chem*. 2009;390(3):191-214. doi:10.1515/BC.2009.033
7. Pizzorno J. Glutathione! *Integr Med (Encinitas)*. 2014;13(1):8-12.